Update
$Akebia Therapeutics(AKBA.US$ Reuters 2 mins ago Akebia Regains Full Rights to Sell Vafseo Tablets in U.S. Following Execution of a Royalty-Based Termination Agreement With CSL Akebia Therapeutics Inc: Regains Full Rights to Sell Vafseo® (Vadadustat) Tablets in U.S. Akebia Therapeutics Inc -Announced Vafseo Wac Pricing of $1,278 for a 30-Day Supply Akebia Therapeutics Inc: Submitted Tdapa Application for Vafseo in June 2024 and Expects Designation on January 1, 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
